Scarica l'app Stockscreener
28.94
1.58%
0.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$28.49
Aprire:
$28.34
Volume 24 ore:
4.28M
Relative Volume:
0.63
Capitalizzazione di mercato:
$20.71B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
5.1221
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
+6.59%
1M Prestazione:
+28.45%
6M Prestazione:
+141.37%
1 anno Prestazione:
+178.81%
Intervallo 1D:
$28.30
$28.96
Intervallo di 1 settimana:
$27.03
$29.20
Portata 52W:
$8.73
$29.20
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
28.94 | 20.39B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Fox Run Management L.L.C. Invests $877,000 in Roivant Sciences Ltd. $ROIV - MarketBeat
Liquidity Mapping Around (ROIV) Price Events - Stock Traders Daily
IPO Launch: Can Roivant Sciences Ltd outperform under higher oil pricesMarket Performance Report & Weekly Top Performers Watchlists - baoquankhu1.vn
Analyst Downgrade: What is the dividend yield of Roivant Sciences LtdJuly 2025 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Vanguard Group Inc. Has $587.12 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock hits all-time high at 27.95 USD - Investing.com India
Roivant Sciences (ROIV) Price Target Increased by 18.98% to 32.44 - Nasdaq
Support Test: Should I hold or sell Roivant Sciences Ltd nowMarket Performance Summary & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Roivant Sciences (NASDAQ:ROIV) Sets New 52-Week HighShould You Buy? - MarketBeat
Roivant Sciences stock hits all-time high at 27.95 USD By Investing.com - Investing.com South Africa
Roivant Sciences (NASDAQ:ROIV) Insider Sells $27,492,361.50 in Stock - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Insider Sells $16,159,098.90 in Stock - MarketBeat
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells 1,400,000 Shares of Stock - MarketBeat
Aug Chart Watch: What is the dividend yield of Roivant Sciences LtdTreasury Yields & Reliable Trade Execution Plans - baoquankhu1.vn
Roivant Sciences Ltd. (ROIV) Investor Outlook: Analyzing Its 16.86% Potential Upside - DirectorsTalk Interviews
Published on: 2026-02-21 23:52:14 - baoquankhu1.vn
CenterBook Partners LP Grows Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Risk Off: Can Veracyte Inc ride the EV waveQuarterly Profit Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
Why Roivant Sciences Ltd. (87S) stock appeals to dividend investorsTrade Ideas & Long-Term Growth Plans - mfd.ru
Why (ROIV) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Roivant Sciences Advances PHocus Trial Milestone As Shares Trade Below Targets - simplywall.st
Roivant Sciences PHocus Trial Milestone Highlights Pipeline Progress And Valuation Gap - Yahoo Finance
Momentum Shift: Is Roivant Sciences Ltd backed by strong institutional buying2025 Growth vs Value & Short-Term Trading Alerts - baoquankhu1.vn
Is Roivant Sciences Ltd. stock a contrarian buyJuly 2025 Trade Ideas & Weekly High Return Forecasts - mfd.ru
Roivant Sciences Advances PH Programs As Investors Weigh Pipeline Milestones - simplywall.st
Citi raises Roivant Sciences (ROIV) PT to $35 following positive phase 2 brepocitinib data - MSN
Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data - Insider Monkey
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 375,784 Shares of Stock - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 425,000 Shares - MarketBeat
Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out - The Motley Fool
HC Wainwright Analysts Increase Earnings Estimates for ROIV - MarketBeat
Is Roivant Sciences Ltd. stock undervalued right now2025 Short Interest & AI Based Buy and Sell Signals - mfd.ru
Can Roivant Sciences Ltd. lead its sector in growthLayoff News & Detailed Earnings Play Alerts - mfd.ru
Roivant Sciences (NASDAQ:ROIV) Insider Sells $8,985,003.27 in Stock - MarketBeat
Impax Asset Management Group plc Sells 200,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs - Investing.com Australia
Candriam S.C.A. Increases Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences stock price target raised to $33 from $26 at H.C. Wainwright - Investing.com Australia
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV)Here's Why - Finviz
Citi raises Roivant Sciences stock price target to $35 from $26 - Investing.com Australia
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs By Investing.com - Investing.com South Africa
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) – Here’s Why - Insider Monkey
Roivant Sciences stock hits all-time high at 26.35 USD - Investing.com Australia
Roivant Sciences stock hits all-time high at 26.35 USD By Investing.com - Investing.com Canada
Roivant Sciences Earnings Call Highlights Brepocitinib Surge - TipRanks
Deep Dive Into Roivant Sciences Stock: Analyst Perspectives (4 Ratings) - Benzinga
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib phase III launch in 2026 - MSN
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Roivant Sciences Ltd Azioni (ROIV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Torti Frank | President and Vant Chair |
Feb 20 '26 |
Option Exercise |
3.85 |
1,012,610 |
3,898,548 |
14,749,157 |
| Torti Frank | President and Vant Chair |
Feb 23 '26 |
Option Exercise |
3.85 |
587,390 |
2,261,452 |
14,323,937 |
| Torti Frank | President and Vant Chair |
Feb 19 '26 |
Sale |
27.42 |
1,400,000 |
38,388,000 |
13,736,547 |
| Torti Frank | President and Vant Chair |
Feb 20 '26 |
Sale |
27.15 |
1,012,610 |
27,492,362 |
13,736,547 |
| Torti Frank | President and Vant Chair |
Feb 23 '26 |
Sale |
27.51 |
587,390 |
16,159,099 |
13,736,547 |
3.60%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):